Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Diffusion Capacity Defect by REGEND001 Cell Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

December 6, 2022

Primary Completion Date

July 9, 2025

Study Completion Date

July 9, 2025

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

REGEND001 cell therapy

Transplantation of the cell product

DRUG

Placebo

Transplantation of Placebo

Trial Locations (8)

215006

The First Affiliated Hospital of Soochow University, Suzhou

330006

The First Affiliated Hospital of Nanchang University, Nanchang

410008

Xiangya Hospital of Central South University, Changsha

Unknown

China-Japan Friendship Hospital, Beijing

The Southwest Hospital of AMU, Chongqing

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

Shanghai East Hospital, Shanghai

Zhongshan Hospital affiliated to Fudan University, Shanghai

All Listed Sponsors
collaborator

The First Affiliated Hospital of Guangzhou Medical University

OTHER

collaborator

Southwest Hospital, China

OTHER

collaborator

Shanghai Zhongshan Hospital

OTHER

collaborator

China-Japan Friendship Hospital

OTHER

collaborator

Shanghai East Hospital

OTHER

collaborator

Regend Therapeutics XLotus (Jiangxi) Co, Ltd.

UNKNOWN

collaborator

The First Affiliated Hospital of Nanchang University

OTHER

collaborator

Xiangya Hospital of Central South University

OTHER

collaborator

The First Affiliated Hospital of Soochow University

OTHER

lead

Regend Therapeutics

INDUSTRY